Gapping down
In reaction to earnings/guidance:
- PLTR -13.4%, AU -6.1%, ELAN -5%, WOW -5%, BEAM -4.4%, KOS -3.8%, HGV -3.3%, RDNT -2.6%, PRM -2.4%, TWKS -1.4%, MAC -1.4%, AZUL -0.9%
Select ETFs showing weakness:
- GDX -3.3%, USO -3.2%, SLV -2.6%, QQQ -2.5%, SMH -2.5%, XLE -2.3%, SPY -1.9%, IWM -1.9%, IGV -1.8%, DIA -1.7%, GLD -1%
Other news:
- SJR -14.3% (Rogers And Shaw (SJR) Remain Committed To Merger Following Notification By The Commissioner Of Competition)
- ALLK -3.5% (files for $250 mln common stock offering)
- VLDR -3.4% (files for $300 mln mixed securities shelf offering; also files for 9,898,508 share common stock offering by selling shareholder)
- JAZZ -3% (has completed the divestiture of Sunosi (solriamfetol) in the U.S. to Axsome Therapeutics)
- MYOV -2.5% (Myovant Sciences and Accord Healthcare enter into exclusive license agreement to commercialize ORGOVYX for advanced hormone-sensitive prostate cancer in Europe)
- CTVA -2.2% (files mixed securities shelf offering )
- CHDN -2% (reports Kentucky Derby week handle up 25% yr/yr)
- RADI -1.8% (rumors RADI is exploring options including a sale)
- KW -1.3% (files mixed securities shelf offering) .
Analyst comments:
- ARVN -7.6% (downgraded to Neutral from Outperform at Wedbush)
- SPCE -5% (downgraded to Hold from Buy at Truist)
- IHRT -3.4% (downgraded to Neutral from Overweight at JP Morgan)
- DISH -3.4% (downgraded to Neutral from Overweight at JP Morgan)
- ACMR -2.8% (downgraded to Neutral from Buy at Goldman)
- BKU -2.2% (downgraded to Underweight from Neutral at Piper Sandler)
- NVS -1.8% (downgraded to Peer Perform from Outperform at Wolfe Research)
- BKI -1.3% (downgraded to Mkt Perform from Outperform at Keefe Bruyette)